News & Updates
Filter by Specialty:
Progressive phenotype predicts transplantation-free survival in ILD, IPF patients
Nearly one in four nonidiopathic pulmonary fibrosis (non-IPF) patients with a fibrosing form of interstitial lung disease (FILD) develop a progressive phenotype relative to almost 60 percent of IPF patients, reveals a study. Survival of non-IPF FILD patients with such phenotype is similar to IPF.
Progressive phenotype predicts transplantation-free survival in ILD, IPF patients
02 May 2022
Annual flu jab in HF patients may lower hospitalization, pneumonia risk
An annual influenza vaccination does not lower the risk of cardiovascular (CV) outcomes in patients with heart failure (HF), though it may reduce the risk of pneumonia and hospitalization, according to results of the IVVE study presented at ACC.22.
Annual flu jab in HF patients may lower hospitalization, pneumonia risk
27 Apr 2022
Prolonged QTc in hospitalized COVID-19 patients tied to increased mortality risk
Prolonged corrected QT interval (QTc), as determined via electrocardiogram (ECG), may indicate an elevated risk of myocardial injury and death in patients hospitalized for COVID-19, according to a prospective study from Israel presented at EHRA 2022.
Prolonged QTc in hospitalized COVID-19 patients tied to increased mortality risk
25 Apr 2022
Furmonertinib emerges as potential first-line option for EGFRm NSCLC
Treatment-naïve patients with locally advanced or metastatic EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC) experience improved progression-free survival (PFS) when treated with furmonertinib compared with gefitinib, according to results of the phase III FURLONG study.
Furmonertinib emerges as potential first-line option for EGFRm NSCLC
22 Apr 2022
SPOTLIGHT: Durvalumab shines in real-world trial on NSCLC
Findings from the SPOTLIGHT trial have shown the efficacy of administering durvalumab after chemoradiotherapy (CRT) in patients with unresectable stage III non-small-cell lung cancer (NSCLC).
SPOTLIGHT: Durvalumab shines in real-world trial on NSCLC
21 Apr 2022
CVT risk higher after COVID-19 than COVID-19 mRNA vaccine
An observational study from Singapore has shown that the incidence of cerebral venous thrombosis (CVT) following SARS-CoV-2 infection is greater than that following receipt of an mRNA-based SARS-CoV-2 vaccine.
CVT risk higher after COVID-19 than COVID-19 mRNA vaccine
20 Apr 2022
Acute kidney, liver injury risks with remdesivir pinned to underlying SARS-CoV-2 infection
Treatment with remdesivir in patients hospitalized for COVID-19 does not appear to confer increased risks of acute kidney and liver injury, with a recent study showing that these risks are already elevated even before exposure to treatment and there is no further increase following remdesivir initiation.
Acute kidney, liver injury risks with remdesivir pinned to underlying SARS-CoV-2 infection
18 Apr 2022
Early molnupiravir use benefits unvaccinated COVID-19 outpatients
Early administration (ie, within 5 days after symptom onset) of the oral, small-molecule antiviral prodrug molnupiravir slashed the risk of hospitalization or death in at-risk, unvaccinated, nonhospitalized adults with mild-to-moderate COVID-19, findings from the phase III component of the phase II/III MOVe-OUT trial have shown.